Strategic Collaboration Signed to Advance Metabolic Disorder Treatments
Zealand Pharma and OTR Therapeutics enter into an agreement combining obesity expertise and a proprietary research platform to create next-generation oral small-molecule therapeutics.
Zealand Pharma A/S and OTR Therapeutics have announced a strategic collaboration and license agreement focused on the discovery and development of novel therapeutics for metabolic diseases. The partnership aims to broaden treatment options for patients with metabolic disorders.
-
Collaboration Focus: The agreement combines Zealand Pharma’s deep expertise in obesity and metabolic health with OTR Therapeutics’ proprietary research platform and capabilities in drug discovery and development. The core focus is on creating next-generation oral small-molecule therapeutics.
-
Responsibilities:
-
OTR Therapeutics: Will be responsible for leading the research and preclinical development phases, utilizing its proprietary discovery platform.
-
Zealand Pharma: Will manage the clinical development, regulatory submissions, and global commercialization of the resulting products.
-
-
Financial Terms:
-
OTR Therapeutics will receive an upfront payment of $20 million, with the potential to increase to $30 million based on certain conditions.
-
The total potential consideration, largely tied to commercial milestones, could reach up to approximately $2.5 billion through milestone payments associated with preclinical, development, regulatory, and commercial achievements.
-
OTR Therapeutics will also be eligible to receive tiered single-digit royalties on the worldwide net sales of any products that emerge from this collaboration.
-
A representative from Zealand Pharma noted that the multi-program partnership will expand their metabolic health pipeline into oral small-molecule therapeutics for targets where they possess deep biological expertise, effectively complementing the company’s existing strong peptide R&D platform.
